GSK · GSK plc
$48.13
+0.02% last session
End-of-day data · close of 2026-09-11
Market cap
$96B
Enterprise value
$111B
Trailing P/E
15.1
Forward P/E
9.7
Dividend yield
4.0%
Beta
0.29
Avg volume
4M
Employees
67K
Daily Change %
0.02%
5 Days Change
-3.55%
10 Days Change
-5.01%
30 Days Change
-3.47%
60 Days Change
-7.14%
Month to Day Change
-5.01%
Year to Day Change
0.72%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — GSK
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-01-06
Latest call per bank · past 12 months
Barclays
Underweight$0.00
-100.0% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-01-06 | Barclays | Downgrade | Equal-Weight → Underweight | $0.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 36 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 5.8% below the 50-day MA ($51.07).
- Price vs 200-day MA: Trading 6.5% below the 200-day MA ($51.49).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.33) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($38.17) and high ($59.60).
GSK Price Chart
Loading chart for GSK…
Fundamentals
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.
More in Drug Manufacturers - General
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.